scholarly journals Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease

2016 ◽  
Vol 60 (4) ◽  
pp. 2564-2566 ◽  
Author(s):  
José Moltó ◽  
Fredzzia Graterol ◽  
Cristina Miranda ◽  
Saye Khoo ◽  
Ioana Bancu ◽  
...  
Keyword(s):  
Renal Disease ◽  
Protein Binding ◽  
End Stage Renal Disease ◽  
Inhibitory Concentration ◽  
Plasma Concentrations ◽  
Extraction Ratio ◽  
Dialysis Session ◽  
Registration Number ◽  
Stage Renal Disease ◽  
End Stage

ABSTRACTData on dolutegravir removal by hemodialysis are lacking. To study this, we measured dolutegravir plasma concentrations in samples of blood entering and leaving the dialyzer and of the resulting dialysate from 5 HIV-infected patients with end-stage renal disease. The median dolutegravir hemodialysis extraction ratio was 7%. The dolutegravir concentrations after the dialysis session remained far above the protein-binding-adjusted inhibitory concentration. Our results show minimal dolutegravir removal by hemodialysis, with no specific dolutegravir dosage adjustments required in this setting. (This study is registered at ClinicalTrials.gov under registration number NCT02487706.)

MO788ERYPTOSIS AND PARATHORMONE IN PATIENTS WITH END STAGE RENAL DISEASE TREATED BY HEMODIALYSIS

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Aya Hefny ◽  
Fatima El-Tahir ◽  
Abeer Fikry ◽  
Ali M Shendi
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Annexin V ◽  
Dialysis Session ◽  
Multilinear Regression ◽  
Multilinear Regression Analysis ◽  
Stage Renal Disease ◽  
End Stage ◽  
Conventional Hemodialysis ◽  
Pth Level

Abstract Background and Aims Eryptosis (Red cell apoptosis) has been recognized as one of the mechanisms that mediate anaemia in patients with chronic kidney disease whether pre or on dialysis. Phosphorus (Ph) and parathormone (PTH) can be considered as uremic toxins which are associated with renal anaemia, and both were suggested to be associated with shortened red blood cell (RBC) life span. We aimed to assess the relation between each of PTH and phosphorus levels and eryptosis in a cohort of patients with end stage renal disease (ESRD) treated by haemodialysis. Method We studied a cohort of 85 patients with ESRD on conventional hemodialysis for at least 3 months. Blood was drawn prior to the mid-week dialysis session. Patients are dialysed on Fresenius 4008s machines. The percent of Annexin V-binding RBCs was assessed by flow cytometry in fresh blood samples and was used to indicate the percent of Eryptotic RBCs. Data were represented as median (interquartile range). Results The study included 85 patients on prevalent hemodialysis for a median of 8 (3-12) years, 52.9% females. Hypertension was the most common cause of ESRD (49.4%). The median hemoglobin was 10.9 (9.3 - 13) gm/dl and most patients received erythropoietin therapy (83/85) at a median dose of 8000 (4000 – 8000 units/weak). The median percent of Annexin V- binding RBCs was 2.3 (1.4 – 4.7%). On multilinear regression analysis, only PTH was independently associated with the percent of Annexin V- binding RBCs (standardized β= 0.630; 95.0% CI: 0.001 – 0.003; p<0.001). Patients were then stratified according to the PTH level into: low PTH (< 150 ng/dl; 25/85, 29.4%), target PTH (150 – 600 ng/dl; 33/85, 38.8%) and high PTH (> 600 ng/dl; 27/85, 31.8%) groups. The 3 groups differed significantly in the percent of Annexin V- binding RBCs (1.2 (0.7-1.7); 2.5 (1.8-3.6) and 4.8 (3.2-5.6) % respectively; p<0.001) (Figure). The percent of Annexin V- binding RBCs was similar in patients with high (>5.5) and target (<5.5 mg/dl) Ph levels (p=0.318). It was higher in patients with above-target CaXPh product (>55) than those with target CaXPh product (<55 mg2/dl2) (5 (2-5.4) % vs 2.3 (4.1 – 1.2) %), yet this was not statistically significant (p=0.068). Conclusion Patients with ESRD treated by hemodialysis express high rates of eryptosis. Parathormone excess in those patients may result in further eryptosis enhancement, and this represents a potential pathogenic mechanism linking hyperparathyroidism with the anemia of CKD. Larger interventional studies are thus warranted to further explore the association between parathormone and eryptosis.

Increased Levels Of Tissue Factor, Adhesion Molecules, Nitric Oxide and Adiponectin In End Stage Renal Disease. A Complex Interplay

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 4742-4742
Author(s):  
Jawed Fareed ◽  
Kristiyana Kaneva ◽  
Debra Hoppensteadt ◽  
Vinod Bansal
Keyword(s):  
Nitric Oxide ◽  
Renal Disease ◽  
Tissue Factor ◽  
Adhesion Molecules ◽  
End Stage Renal Disease ◽  
Esrd Patient ◽  
Dialysis Session ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Introduction End stage renal disease (ESRD) represents the fifth (final) stage of chronic kidney disease characterized by an established kidney failure (GFR <15 mL/min/1.73 m2). To further understand the pathophysiology of ESRD, this study was designed to measure the circulating levels of tissue factor (TF), adhesion molecules, such as p-selectin (P-Sel), soluble ICAM (s-ICAM), nitric oxide and adiponectin (AD). Methods This study included 119 ESRD patients undergoing maintenance hemodialysis in conjunction with an ongoing IRB approved protocol on the profiling of inflammatory markers in this syndrome. Citrated blood plasma samples were collected from these patients prior to the routine dialysis session. Nitric oxide levels (NO) were measured using a commercial kit from R&D systems (Minneapolis, Minnesota) and ELISA based methods for TF, P-Sel, s-ICAM and adiponectin were also purchased from R&D systems. Chromogenic and thrombin substrate method were used to measure the anti-Xa activity thrombin generation. Results Tissue factor levels were found to be increased in the ESRD group (20.4±6.1pg/ml) vs the control (11.9±2.8pg/ml). The nitric oxide level was markedly higher in the ESRD group (32±17uM) vs the controls (7±3uM). The p-selectin levels were also elevated in the ESRD group (46±20ng/ml) vs the control (31±3ng/ml). The soluble ICAM levels were higher in the ESRD group (250±112ng/ml) vs the control (180±19ng/ml). Interestingly, the adiponectin levels were also increased in the ESRD group (19.2±9.3ug/ml) vs the control (11.2±4.1ug/ml). The pre-dialysis samples of the ESRD patients exhibited detectable levels of heparin. Summary/Conclusions These studies suggest that TF, NO, p-selectin and s-ICAM levels are increased in the ESRD patient. It is of interest to note that despite that a significant number of ESRD patients were diabetic; the AD levels were increased in this group. These results suggest that while ESRD represents a pro-inflammatory/hypercoagulable state, the repeated administration of heparin and other drugs may contribute to the regulation of the hemostatic process and inflammatory balance. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Minimal Removal of Raltegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease

2010 ◽  
Vol 54 (7) ◽  
pp. 3047-3048 ◽  
Author(s):  
José Moltó ◽  
José Sanz-Moreno ◽  
Marta Valle ◽  
Samandhy Cedeño ◽  
Jordi Bonal ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Extraction Ratio ◽  
Blood Samples ◽  
Stage Renal Disease ◽  
End Stage

ABSTRACT Little is known about raltegravir removal by hemodialysis in patients with end-stage renal disease (ESRD). We therefore measured raltegravir concentrations in plasma in pre- and postdialyzer blood samples from 2 ESRD HIV-infected patients. The hemodialysis extraction ratio and raltegravir hemodialysis clearance were 5.5% and 9.1 ml/min in patient 1 and 9.5% and 19.1 ml/min in patient 2, respectively. Our results suggest minimal raltegravir removal by hemodialysis with no specific raltegravir dosage adjustments required in HIV-infected patients undergoing hemodialysis.

Prevalence and Severity of Itching in Patients with End-Stage Renal Disease: Treatment with Nalfurafine Hydrochloride

2019 ◽  
Vol 47 (Suppl. 2) ◽  
pp. 45-49 ◽  
Author(s):  
Hidetomo Nakamoto ◽  
Takehito Kobayashi ◽  
Toru Noguchi ◽  
Takeru Kusano ◽  
Keigo Ashitani ◽  
...  
Keyword(s):  
Conservative Treatment ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Dialysis Session ◽  
Disease Treatment ◽  
Uremic Pruritus ◽  
Oral Medications ◽  
Significant Difference ◽  
Stage Renal Disease ◽  
End Stage

Background/Aims: In this study, we investigated the severity and frequency of uremic pruritus and itch-associated insomnia in patients with end-stage renal disease (ESRD) or chronic kidney disease (CKD). Methods: This questionnaire-based study included outpatients with ESRD or CKD who were attending Tokorozawa Renal Clinic in Saitama Prefecture or Musashi Ranzan Hospital and were stable on treatment. The questionnaire was completed by patients on hemodialysis (HD) before a dialysis session and by patients on peritoneal dialysis (PD) or conservative treatment at the time of an outpatient hospital visit. Results: Itching was reported by 61.6% of patients on HD, 61.5% on PD, and 43.2% on conservative CKD management. There was no statistically significant difference in the severity or frequency of itch according to whether patients were on HD for ESRD, PD for ESRD, or receiving conservative treatment for CKD. However, insomnia was significantly more common in the PD group than in the HD and conservative CKD groups. Conclusion: Better skin management is needed for itch in patients with ESRD or CKD. Moisturizing and lifestyle factors are important. Topical or oral medications may also be used. Nalfurafine, a κ receptor agonist, is now available in Japan for the treatment of uremic pruritus in these patients.

scholarly journals Increased plasma concentrations of LDL-unbound apo(a) in patients with end-stage renal disease: Rapid Communication

1997 ◽  
Vol 52 (6) ◽  
pp. 1685-1692 ◽  
Author(s):  
Evi Trenkwalder ◽  
Alexandra Gruber ◽  
Paul König ◽  
Hans Dieplinger ◽  
Florian Kronenberg
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Plasma Concentrations ◽  
Rapid Communication ◽  
Stage Renal Disease ◽  
End Stage

Pharmacokinetics and Protein Binding of Eprosartan in Hemodialysis-Dependent Patients with End-Stage Renal Disease

1999 ◽  
Vol 19 (5) ◽  
pp. 612-619 ◽  
Author(s):  
Steven J. Kovacs ◽  
David M. Tenero ◽  
David E. Martin ◽  
Bernard E. Ilson ◽  
Diane K. Jorkasky
Keyword(s):  
Renal Disease ◽  
Protein Binding ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Preoperative Evaluation in Patients With End-Stage Renal Disease and Chronic Kidney Disease

2017 ◽  
Vol 10 ◽  
pp. 117863291771302 ◽  
Author(s):  
Rabih Nasr ◽  
Sridhar Chilimuri
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Preoperative Evaluation ◽  
Dialysis Session ◽  
Dialysis Access ◽  
Dialysis Patients ◽  
Stage Renal Disease ◽  
End Stage

Optimal preoperative management of dialysis patients remains challenging. Patients with end-stage renal disease (ESRD) have higher mortality in the perioperative setting compared with non-ESRD patients. However, it is well established that dialysis should be done on the day before surgery. Additional dialysis session prior to surgery does not improve outcomes. All dialysis patients should undergo blood work to check electrolytes and especially serum potassium prior to any surgery. Some medications, including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and diuretics, should be stopped prior to surgery to minimize hemodynamic changes during surgery. The dialysis access should be carefully examined for any signs of infection. The arteriovenous fistula or graft should be evaluated for patency. Glycemic control in diabetic ESRD and chronic kidney disease patients is very important, and clinicians should be aware of the risk of bleeding and the appropriate analgesics that can be used in dialysis patients in the perioperative setting. In conclusion, preoperative evaluation in patients with ESRD should be a multidisciplinary approach.

Sign in / Sign up

Export Citation Format

Share Document